Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
A phase II study of weekly alternating chemotherapy in extensive-stage small cell lung cancer
Autore:
Kalemkerian, GP; Ali, MA; Luthra, K; Wozniak, AJ; Valdivieso, M; Kraut, MJ;
Indirizzi:
Wayne State Univ, Dept Med, Div Hematol & Oncol, Detroit, MI 48202 USA Wayne State Univ Detroit MI USA 48202 atol & Oncol, Detroit, MI 48202 USA Barbara Ann Karmanos Canc Inst, Detroit, MI USA Barbara Ann Karmanos Canc Inst Detroit MI USA Canc Inst, Detroit, MI USA
Titolo Testata:
CANCER INVESTIGATION
fascicolo: 3, volume: 19, anno: 2001,
pagine: 234 - 238
SICI:
0735-7907(2001)19:3<234:APISOW>2.0.ZU;2-H
Fonte:
ISI
Lingua:
ENG
Soggetto:
INTENSIVE WEEKLY CHEMOTHERAPY; RANDOMIZED TRIAL; CYCLOPHOSPHAMIDE; DOXORUBICIN; VINCRISTINE; CISPLATIN; ETOPOSIDE; REGIMENS;
Keywords:
chemotherapy; extensive-stage disease; small cell lung cancer;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
15
Recensione:
Indirizzi per estratti:
Indirizzo: Kalemkerian, GP Univ Michigan, Med Ctr, 1366 Canc Ctr 0922,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA Univ Michigan 1366 Canc Ctr 0922,1500 E Med CtrDr Ann Arbor MI USA 48109
Citazione:
G.P. Kalemkerian et al., "A phase II study of weekly alternating chemotherapy in extensive-stage small cell lung cancer", CANCER INV, 19(3), 2001, pp. 234-238

Abstract

Despite the recent development of new chemotherapeutic agents with activity in small cell lung cancer (SCLC), the long-term prognosis of patients with extensive-stage disease remains poor and has not improved in the past 20 years. The present study was designed to evaluate the activity and toxicityof weekly. alternating-regimen chemotherapy in patients with extensive-stage SCLC. Patients with previously untreated extensive-stage SCLC and performance status 0-2 were treated with cyclophosphamide 250 mg/m(2), etoposide 100 mg/m(2), and cisplatin 50 mg/m(2) on day I; vincristine I mg/m2 on day 8; and ifosfamide 1.2 gm/m(2) on days 8 and 9 with the entire treatment repeated every 14 days. Eighteen patients received chemotherapy for a median of 14 weeks (range, 1-35 weeks). Seventeen patients (94%) required dose delays and 16 patients (89%) required at least one dose reduction due to toxicity. Twelve patients (67%) exhibited cm objective response (I complete re sponse, I I partial response) with a median duration of response of 18 weeks (range, 8-32 weeks). Median survival was 33 weeks (range, 1-57 weeks) with a I-year survival rate of 22%. Toxicity was primarily hematologic, including grade 3-4 leukopenia (82% of patients) and anemia (53% of patients). Only2 patients developed grade 3 peripheral neuropathy and none exhibited grade 3-4 renal insufficiency. This regimen of weekly alternating combination chemotherapy resulted in tolerable toxicity as well as response and survivalrates comparable to those achieved with standard chemotherapy in patients with extensive-stage SCLC. However, weekly chemotherapy regimens for the treatment of SCLC remain investigational.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 31/03/20 alle ore 16:24:14